常州千红生化制药股份有限公司 独立董事 2023 年度述职报告 各位股东及股东代表： 本人作为常州千红生化制药股份有限公司（以下简称"公司"）的独立董事， 根据《公司法》、《证券法》、《上市公司治理准则》、《上市公司独立董事管理办法》 等相关法律、法规以及《公司章程》、《独立董事工作制度》等有关规定和要求， 认真履行职责，谨慎、勤勉地行使公司所赋予的权利，充分发挥独立董事的独立 性作用，维护了公司的整体利益和全体股东特别是社会公众股股东的合法权益。 现将 2023 年度本人履行独立董事职责情况述职如下： （一）工作履历、专业背景及兼职情况 一、独立董事基本情况 本人徐光华，男，1963 年 4 月出生，中国国籍，无境外永久居留权，管理学 博士。1985 年 7 月至 1994 年 8 月，历任江苏科技大学助教、讲师；1994 年 9 月 至 2004 年 5 月，历任东南大学讲师、副教授；2004 年 6 月至今，历任南京理工 大学副教授、教授、博士生导师、九三学社主委；2021 年 1 月至 2024 年 1 月， 担任公司独立董事（届满后离任）。现兼任江苏靖江农村商业银行股份有限公司 监事，江苏宁沪高速公 ...

Financial Performance - The company's revenue for Q1 2024 was ¥461,101,487.65, a decrease of 24.19% compared to ¥608,218,905.42 in the same period last year[5] - Net profit attributable to shareholders increased by 21.13% to ¥104,108,160.35 from ¥85,946,847.70 year-on-year[5] - Total operating revenue for Q1 2024 was ¥461.10 million, a decrease of 24.2% compared to ¥608.22 million in the same period last year[19] - Net profit for Q1 2024 was ¥101.35 million, an increase of 21.3% from ¥83.55 million in the previous year[20] - The total comprehensive income for Q1 2024 was ¥100.02 million, compared to ¥83.51 million in the same period last year, marking an increase of 19.8%[22] Cash Flow - The net cash flow from operating activities surged by 709.36% to ¥171,109,914.54, compared to a negative cash flow of ¥28,080,310.76 in the previous year[5] - Cash flow from operating activities generated ¥171.11 million, a significant improvement compared to a negative cash flow of ¥28.08 million in Q1 2023[23] - The net cash flow from investment activities was 81,085,341.57 CNY, a significant improvement compared to -107,460,996.87 CNY in the previous year[24] - The total cash and cash equivalents at the end of the period reached 684,246,877.47 CNY, up from 470,466,348.14 CNY year-over-year[24] - Cash inflow from financing activities was 200,000,000.00 CNY, while cash outflow totaled 140,967,339.59 CNY, resulting in a net cash flow of -140,967,339.59 CNY[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,728,721,168.25, a decrease of 1.35% from ¥2,766,081,444.15 at the end of the previous year[5] - As of March 31, 2024, the total assets amounted to ¥2,728,721,168.25, a decrease from ¥2,766,081,444.15 at the beginning of the period[17] - The total liabilities increased slightly to ¥295,558,850.13 from ¥292,172,947.64[17] - The non-current assets totaled ¥1,149,086,990.33, showing a slight increase from ¥1,140,104,674.78[17] Shareholder Information - Basic earnings per share rose by 23.07% to ¥0.0827 from ¥0.0672 in the same period last year[5] - Earnings per share (EPS) for Q1 2024 was ¥0.0827, up from ¥0.0672 in the same period last year, reflecting a growth of 23.5%[22] - The company completed a share repurchase plan, acquiring a total of 25,000,000 shares, representing 1.95% of the total share capital[14] - The company’s total equity attributable to shareholders was ¥2.42 billion, a slight decrease from ¥2.45 billion year-on-year[21] Operational Efficiency - The company reported a 41.52% decrease in operating costs, primarily due to lower raw material procurement costs compared to the previous year[11] - Total operating costs decreased by 33.4% to ¥344.36 million from ¥517.22 million year-on-year[19] - Research and development expenses were ¥17.48 million, down 15.4% from ¥20.59 million year-on-year, indicating a focus on cost management[19] Other Financial Metrics - The company reported a financial asset fair value change gain of ¥430,734.45, compared to a gain of ¥166,547.42 in the previous year[21] - The company reported a decrease in short-term borrowings to ¥56,213,623.54 from ¥55,622,730.90[17] - The company’s other receivables decreased significantly to ¥4,631,227.88 from ¥16,904,047.16, a decline of approximately 72.6%[15] - Other receivables decreased by 72.6% compared to the beginning of the period, mainly due to compensation received by a subsidiary[11] Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[20] Accounting Changes - The company did not undergo an audit for the first quarter report[25] - The company has adopted new accounting standards starting from 2024, affecting the financial statements[25]

常州千红生化制药股份有限公司 2023 年度审计报告 常州千红生化制药股份有限公司 2023 年度财务审计报告 股票简称：千红制药 股票代码：002550 披露时间：2024 年 4 月 26 日 1 常州千红生化制药股份有限公司 2023 年度审计报告 一、审计报告 | 审计意见类型 | 标准的无保留意见 | | --- | --- | | 审计报告签署日期 | 2024 年 04 月 24 日 | | 审计机构名称 | 公证天业会计师事务所(特殊普通合伙) | | 审计报告文号 | 苏公 W[2024]A 号 | | 注册会计师姓名 | 秦志军 许国颖 | 审计报告正文 审计报告 苏公 W[2023]A 号 常州千红生化制药股份有限公司全体股东： 一、审计意见 我们审计了常州千红生化制药股份有限公司（以下简称千红制药）财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母 公司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了千红制药 2023 年 12 ...

证券代码：002550 证券简称：千红制药 公告编号：2024-018 常州千红生化制药股份有限公司 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）第六届董事 会第三次会议通知于 2024 年 4 月 12 日通过邮件方式送达，会议于 2024 年 4 月 24 日在公司会议室召开，会议应参加董事 9 人，实参加 9 人。公司监事、高级 管理人员等应邀人员列席会议，会议由董事长王耀方先生召集并主持。本次会议 的通知、召开以及董事出席人数和表决人数符合《公司法》和本公司《公司章程》 的有关规定，本次会议所形成的有关决议合法、有效。 本次董事会会议形成决议如下： 一、审议并通过了《2023 年经营工作报告和 2024 年公司经营工作计划的议 案》 表决结果：9 票同意，0 票弃权，0 票反对，议案获得通过。 二、审议并通过了《2023 年董事会工作报告和 2024 年公司发展规划的议 案》 表决结果：9 票同意，0 票弃权，0 票反对，议案获得通过。 《2023 年董事会 ...

常州千红生化制药股份有限公司 2023 年度股东大会议案汇编 常州千红生化制药股份有限公司 江苏省常州市新北区云河路 518 号 2023 年度股东大会议案汇编 股票简称：千红制药 股票代码：002550 1 | 1. | 2023 | 年董事会工作报告和 2024 年公司发展规划的议案 3 | | --- | --- | --- | | 2. | 2023 | 年监事会报告的议案 8 | | 3. | 2023 | 年公司财务情况报告的议案 11 | | 4. | 2023 | 年公司年度报告全文及其摘要的议案 15 | | 5. | 2023 | 年公司董事、监事、高级管理人员薪酬的议案 16 | | 6. | | 常州千红生化制药股份有限公司利润分配政策及未来三年股东回报规划 | | | （2024 | 年-2026 年） 18 | | 7. | 2023 | 年公司利润分配的议案 25 | | 8. | 2024 | 年公司及其控股子公司向银行申请年度授信额度的议案 26 | 1. 深耕国内市场酶制剂与肝素类制剂，提高品牌核心竞争力 报告期内，董事会与经营管理机构加强对药品集采影响的研判，通过高层专 ...

常州千红生化制药股份有限公司内部控制规则落实自查表 常州千红生化制药股份有限公司内部控制规则落实自查表 | 1、公司是否在首次公开发行股票上市后 10 | | | | | --- | --- | --- | --- | | 个交易日内通过深交所业务专区"资料填报： | | | | | 关联人数据填报"栏目向深交所报备关联人信 | 是 | | | | 息。关联人及其信息发生变化的，公司是否 | | | | | 在 2 个交易日内进行更新。公司报备的关联 | | | | | 人信息是否真实、准确、完整。 | | | | | 2、公司独立董事、监事是否至少每季度查 | 是 | | | | 阅一次公司与关联人之间的资金往来情况。 | | | | | 3、公司是否明确股东大会、董事会对关联 | | | | | 交易的审批权限，制定相应的审议程序，并 | 是 | | | | 得以执行。 | | | | | 4、公司董事、监事、高级管理人员、控股 | 是 | | | | 股东、实际控制人及其关联人是否不存在直 | | | | | 接、间接和变相占用上市公司资金的情况。 | | | | | 六、对外担保的内部控制 | | | ...

证券代码：002550 证券简称：千红制药 公告编号：2024-024 常州千红生化制药股份有限公司 关于继续为控股子公司提供贷款担保的公告 一、担保情况概述 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称："公司"或"本公司"）第六届 董事会第三次会议审议通过了《公司继续为控股子公司提供贷款担保的议案》， 现将担保事项公告如下： 一、担保情况概述 本公司控股子公司江苏众红生物工程创药研究院有限公司（以下简称："江 苏众红"）因研发投入的持续增加及日常运营的需要，需要向银行申请流动资金 贷款授信。 本公司为江苏众红的综合贷款授信继续提供担保，担保金额累计不超过 2000 万元人民币。 上述担保期限均为：自其担保合同生效之日起壹年以内。本次担保事项在董 事会审议范围之内，无需提交股东大会审议。 二、被担保人基本情况 注册地址：常州市新北区云河路 518 号 法定代表人：王耀方 注册资本：980 万美元 主营业务为：生物医药产品与中间体、生物医药试剂、体外诊断试剂、营养 保健品、再生医学材料与制品、功能性生物材料、生物化学产 ...

常州千红生化制药股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称企业内部控制规范体系），结合本公司（以下简称公司）内部控制 制度和评价办法，在内部控制日常监督和专项监督的基础上，董事会对公司在 2023年度（内部控制评价报告基准日为2023年12月31日）的内部控制有效性进行 了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理室负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部 控制评 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥1.81 billion, a decrease of 21.24% compared to ¥2.30 billion in 2022[22]. - The net profit attributable to shareholders for 2023 was approximately ¥181.86 million, down 43.77% from ¥323.41 million in 2022[22]. - The basic earnings per share for 2023 was ¥0.14, a decline of 44.00% from ¥0.25 in 2022[23]. - The total assets at the end of 2023 were approximately ¥2.77 billion, a decrease of 1.42% from ¥2.81 billion at the end of 2022[23]. - The net cash flow from operating activities for 2023 was approximately ¥533.33 million, a significant increase of 846.19% compared to a negative cash flow of ¥71.47 million in 2022[22]. - The company reported a quarterly revenue of ¥608.22 million in Q1 2023, which decreased to ¥348.33 million in Q4 2023[27]. - The company experienced a net loss of approximately ¥15.99 million in Q4 2023, contrasting with a net profit of ¥85.95 million in Q1 2023[27]. - The company reported non-operating income of approximately ¥38.38 million in 2023, down from ¥65.21 million in 2022[30]. - In 2023, the company's revenue was 1.814 billion yuan, a decrease of 21.24% compared to the previous year[48]. - The net profit for 2023 was 182 million yuan, down 43.77% year-on-year[48]. Dividend Distribution - The company plans to distribute a cash dividend of 1.2 CNY per 10 shares to all shareholders, based on a total of 1,249,800,000 shares[4]. - The company distributed a cash dividend of RMB 1.2 per 10 shares, totaling RMB 149,976,000, based on a share base of 1,249,800,000 shares[141]. - The total distributable profit at the end of the reporting period was RMB 873,978,695.92, with the cash dividend representing 100% of the profit distribution[142]. - The company has a mature development stage and aims for a minimum of 80% cash dividend distribution in profit allocation[141]. Market Position and Strategy - The biopharmaceutical industry in which the company operates is experiencing rapid growth, making China the second-largest pharmaceutical market globally after the United States[34]. - The company is a leading enterprise in the domestic biopharmaceutical industry, focusing on innovative drugs and maintaining a leading market share in heparin sodium injection and sealing liquid[36]. - The company has successfully captured market opportunities from national centralized procurement policies, leading to significant growth in the revenue of the Enoxaparin series products[36]. - The company is actively exploring new strategic collaborations, including an OTC strategic partnership with Bayer Pharmaceuticals, to enhance brand recognition and market competitiveness[36]. - The company is positioned to benefit from national policies aimed at encouraging innovation and supporting the development of new drugs, as outlined in the "High-Quality Development Action Plan for the Pharmaceutical Industry (2023-2025)"[39]. - The company has established a professional international marketing team and a network in countries like the USA, Germany, and Japan[44]. - The company is focusing on strategic key customers and new potential markets under the Belt and Road Initiative[48]. Research and Development - The company has established two joint research institutes and an offshore drug research and development center, enhancing its innovation capabilities[37]. - The company has three innovative drugs entering Phase II clinical trials, with one additional innovative drug receiving clinical trial approval, strengthening its core competitiveness[37]. - In 2023, the company applied for 21 invention patents in biopharmaceutical innovation, with one new drug entering phase II clinical trials and three more set to enter soon, enhancing its core competitiveness[49]. - The company is advancing multiple new drug projects, including QHRD107 and QHRD110, which are in various stages of clinical trials aimed at enhancing the product pipeline and core competitiveness[75]. - The company aims to accelerate the R&D process for five new drugs, particularly focusing on the Phase II clinical trial of QHRD107, with the goal of achieving early results in 2024[95]. - The company has allocated a budget of 50 million for R&D in the next fiscal year to support innovation initiatives[120]. Operational Efficiency - The gross profit margin for the biopharmaceutical sector improved to 43.07%, up 4.60% from the previous year[62]. - The company reported a significant increase in other business revenue by 358.99%, reaching ¥5,172,502.21[61]. - The total operating cost decreased by 27.28% to ¥1,028,402,11, with raw materials constituting 94.18% of the total costs[66]. - The company emphasized the importance of optimizing product structure and improving management capabilities to address existing challenges[58]. - The company has established a comprehensive production technology quality management system, with nearly 80,000 square meters of facilities meeting GMP standards, contributing to its competitive edge in both domestic and international markets[50][51]. Risk Management - The company has detailed its future risks and countermeasures in the report, emphasizing the importance of investor awareness regarding investment risks[4]. - The company faces significant risks from drug procurement policies leading to potential price declines in product sales[98]. - Increased investment in new drug research and development poses risks to profit margins due to the lengthy and costly nature of the process[98]. - Rising operational costs are anticipated due to fluctuations in raw material prices, increased labor costs, and higher R&D expenses[99]. - The tightening of environmental policies adds uncertainty and risk to the company's operations[98]. - The company plans to implement a robust risk management system to ensure stable operations across key areas, including sales expense control and strategic investment project oversight[96]. Corporate Governance - The company strictly adheres to corporate governance regulations, ensuring compliance with laws and enhancing operational standards[105]. - The internal audit department is in place to oversee economic operations and compliance with internal controls[107]. - The company has established a clear organizational structure, ensuring independence from controlling shareholders in decision-making processes[111]. - The board of directors held four meetings in 2023, with significant resolutions announced on January 6, April 13, July 21, and October 24, demonstrating active governance and decision-making processes[127]. - The audit committee held 3 meetings, discussing key financial reports and internal audits for 2022[131]. - The company is committed to enhancing its internal control systems and governance practices in line with regulatory requirements[130]. Environmental Responsibility - The company has complied with environmental protection laws and standards, ensuring responsible waste management and emissions control[154]. - The company has established a wastewater treatment station at the Changjiang Road plant, which utilizes a combination of physical and biological processes to meet discharge standards before releasing effluent to the local sewage treatment plant[157]. - The company reported that the concentration of COD in wastewater from the Changjiang Road plant was 45.84 mg/L, significantly below the regulatory limit of 500 mg/L[156]. - The company has implemented an automatic monitoring system for wastewater discharge, including online detection of COD, total nitrogen, pH, and flow rate[158]. - The company has invested in environmental protection measures and has complied with the requirements for environmental protection tax payments[158]. - The company incurred environmental expenses of approximately RMB 4.5817 million during the reporting period, including investments in environmental facilities and pollutant treatment[159]. Workforce and Talent Management - The company has a strong talent pool, with nearly 20 PhDs and over 80 master's degree holders, ensuring a solid foundation for future strategic development[51]. - The company has no retired employees and maintains a workforce with a significant number of highly educated staff, including 111 with master's degrees or higher[136]. - The company emphasizes employee training, offering diverse programs to enhance skills and knowledge, including management training for senior staff[138]. - The company has established a competitive salary system based on performance and market conditions, ensuring fairness and efficiency in compensation[137]. Subsidiaries and Investments - The company has established a new subsidiary, Henan Qianmu Biopharmaceutical Co., Ltd., with a registered capital of ¥100 million, focusing on drug production and related services[70]. - The company has expanded its investment activities through the establishment of Changzhou Qianhong Biotechnology Co., Ltd., with a registered capital of ¥21 million[70]. - The company and Muyuan Food Co., Ltd. jointly invested in establishing Henan Qianmu Biopharmaceutical Co., Ltd. with a registered capital of CNY 100 million, where the company holds a 51% stake[193]. Shareholding and Management Stability - The management team remains stable with no significant changes in shareholding among key executives[114]. - The overall stability in shareholding among executives suggests confidence in the company's strategic direction[114]. - The company reported a total shareholding of 255,400 shares for Wang Yao, with no changes during the period[113]. - The company has appointed new independent directors, including Gao Yu and Ren Xiang, both holding 0 shares[114].

常州千红生化制药股份有限公司 利润分配政策及未来三年股东回报规划（2024 年-2026 年） 为进一步完善和健全常州千红生化制药股份有限公司（以下简称"公司"） 科学、持续、稳定的分红决策和监督机制，保持利润分配政策的连续性和稳定性， 积极回报股东，引导股东树立长期投资和理性投资的理念，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《关于进一步落实上市公司现金分红有关事 项的通知》、《上市公司监管指引第 3 号——上市公司现金分红》等相关法律、法 规、规范性文件以及《常州千红生化制药股份有限公司章程》（以下简称"《公 司章程》"）的相关规定，结合公司的实际情况，特制订以下公司利润分配政策 及未来三年股东回报规划（2024 年-2026 年）： 一、利润分配政策 公司实施利润分配应当遵循以下规定： （一）利润分配顺序 1．公司分配当年税后利润时，应当提取利润的百分之十列入公司法定公积 金。公司法定公积金累计额为公司注册资本的百分之五十以上的，可以不再提取； 2．公司的法定公积金不足以弥补以前年度亏损的，在依照前款规定提取法 定公积金之前，应当先用当年利润弥补亏损； 3．公司从税后利润中提取法定公积 ...